Latigo Biotherapeutics
Latigo Biotherapeutics is a clinical-stage biotechnology company focused on developing innovative non-opioid pain medicines with best-in-class profiles. The company's mission is to provide effective, rapid-acting pain relief without the risk of addiction, targeting pain at its source. Supported by leading investors, Latigo leverages advanced technologies and human genetics to validate its drug targets, aiming to transform pain management and address the opioid epidemic.
Industries
Nr. of Employees
small (1-50)
Products
Oral selective Nav1.8 inhibitor — clinical candidate for acute pain
An orally administered selective small-molecule inhibitor of the Nav1.8 sodium channel developed to block peripheral pain signaling with rapid absorption and a favorable Phase 1 safety and PK profile; progressed through first-in-human studies and received expedited regulatory designation.
Oral selective Nav1.8 inhibitor — clinical candidate for chronic pain
An orally administered selective small-molecule Nav1.8 inhibitor advanced into Phase 1 to evaluate safety, tolerability, and pharmacokinetics for chronic pain indications using SAD and MAD study designs.
Oral selective Nav1.8 inhibitor — clinical candidate for acute pain
An orally administered selective small-molecule inhibitor of the Nav1.8 sodium channel developed to block peripheral pain signaling with rapid absorption and a favorable Phase 1 safety and PK profile; progressed through first-in-human studies and received expedited regulatory designation.
Oral selective Nav1.8 inhibitor — clinical candidate for chronic pain
An orally administered selective small-molecule Nav1.8 inhibitor advanced into Phase 1 to evaluate safety, tolerability, and pharmacokinetics for chronic pain indications using SAD and MAD study designs.
Services
Discovery and translational development of small-molecule ion channel inhibitors
End-to-end discovery workflows including target selection guided by human genetics, structure-based and AI/ML-supported design, in vitro electrophysiology, biomarker development, and preclinical biodistribution to support clinical translation.
Early clinical development and Phase 1 execution
Design and conduct of first-in-human single- and multiple-ascending dose trials with PK, safety, tolerability, relative bioavailability, and food effect assessments.
Discovery and translational development of small-molecule ion channel inhibitors
End-to-end discovery workflows including target selection guided by human genetics, structure-based and AI/ML-supported design, in vitro electrophysiology, biomarker development, and preclinical biodistribution to support clinical translation.
Early clinical development and Phase 1 execution
Design and conduct of first-in-human single- and multiple-ascending dose trials with PK, safety, tolerability, relative bioavailability, and food effect assessments.
Expertise Areas
- Clinical trial management
- Ion channel drug discovery (Nav1.8-focused)
- Translational science and biomarker development
- Medicinal chemistry and lead optimization
Key Technologies
- Voltage-gated sodium channel targeting (Nav1.8)
- Structure-based drug design
- AI/ML-driven drug design
- Patch clamp electrophysiology